Malaysia in Focus: Reverse Cardiac Remodelling
Published: 11 March 2021
-
Views:
2884 -
Likes:
7
-
Views:
2884 -
Likes:
7
-
13m 33sPart 1 Recognising and Treating Cardiac Remodelling in Heart Failure James L Januzzi, David Chew
-
12m 55sPart 2 The Clinical Implications of Cardiac Remodelling in Heart Failure Akshay S Desai, David Chew
-
24m 14sPart 3 Relationships of Cardiac Biomarkers James L Januzzi, Akshay S Desai, David Chew
-
12m 37sPart 4 Prevalence of HFpEF on the Rise – Treat HFpEF as a Whole, Not Just the Comorbidities Andrew JS Coats, David Chew
-
16m 28sPart 5 ARNI: PARAMOUNT, PARAGON-HF, PARALLAX and Putatuve Placebo Analysis Michele Senni, David Chew
Overview
This reverse cardiac remodelling IME programme brings together a leading faculty of internationally-recognised experts, combining presentations and peer-to-peer discussions to provide comprehensive overview of the latest data and opinion around cardiac remodelling.
Beyond the global focus, this programme also seeks – through insight from Dato' Dr David Chew – to frame and contextualise the topics discussed with specific focus on Malaysia, to help support the education of local physicians on pertinent topics including guideline adherence, emerging data, and best practice.
A CPD-accredited version of this programme is available on Radcliffe Education. Click here for further details.
Learning Objectives
- Define cardiac remodelling, with particular focus on the influence of cardiovascular damage, pathogenic risk factors and the structural and functional changes in the left ventricle.
- List the main clinical implications of cardiac remodelling.
- Summarise the relationship between circulating biomarkers, such as NT-proBNP, troponin and sST2, with the extent left ventricular remodelling in subjects with HF.
- Interpret the most recent clinical data from pharmacological and device-based studies in HFrEF and HfpEF.
- Recall the evidence for reverse cardiac remodelling brought about through ARNi therapy, including (but not limited to) PROVE-HF and EVALUATE-HF.
- Review real-world insight into the impact that ARNi therapy has on cardiac reverse remodelling.
Audience
- Practicing cardiologists
- Heart failure specialists
- Health care professionals involved in the diagnosis and management of patients with heart failure
More from this programme
Part 1
Recognising and Treating Cardiac Remodelling in Heart Failure
Part 2
The Clinical Implications of Cardiac Remodelling in Heart Failure
Part 3
Relationships of Cardiac Biomarkers
1 session | |
Relationships of Cardiac Biomarkers | Watch now |
Part 4
Prevalence of HFpEF on the Rise – Treat HFpEF as a Whole, Not Just the Comorbidities
Part 5
ARNI: PARAMOUNT, PARAGON-HF, PARALLAX and Putative Placebo Analysis
Part 6
Overview of the Evidence
1 session | |
Overview of the Evidence | Watch now |
Part 7
Angiotensin Receptor Neprilysin Inhibitors – Renal Safety and Efficacy
Faculty Biographies
Andrew JS Coats
Professor of Cardiology and Scientific Director
Prof Coats is Editor-in-Chief of the Cardiac Failure Review journal. He has published over 20 patents, more than 750 full research papers and more than 120,000 career citations and has a personal H-index of 146. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and will serve as its president from 2020-2022.
Prof Coats is the Immediate past-President of the Heart Failure Association and past-Professor of Cardiology at the University of Warwick, UK. He has also held posts as Head of Cardiology at Imperial College, London and Associate Medical Director and Director of Cardiology at the Royal Brompton and Harefield Hospitals, London. From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine at the University of Sydney.
He is an…
David Chew
Consultant Cardiologist, Cardiac Vascular Sentral Kuala Lumpur, Malaysia.
Dato' Dr David Chew Soon Ping is a Consultant Cardiologist at Cardiac Vascular Sentral Kuala Lumpur (CVSKL) in Malaysia.
He is a Fellow of The Royal College of Physicians (FRCP), London, and a Bachelor of Medicine, and Bachelor of Surgery (MBBS), University of Malaya. Dr Chew is published widely in leading international peer-reviewed journals on the subject of heart failure, and is a member of several societies and professional bodies, including the National Heart Association of Malaysia (NHAM).